arrow_back Back Filing freshness 10-Q FY 2025 SEC EDGAR

RELMADA THERAPEUTICS, INC.

RLMD
$4.93 ▼ -0.45 (-8.36%) at close
Healthcare ·Pharmaceutical Preparations ·USPharmaceutical Preparations
15 Visible periods
23 Metrics
Peer-ranked Benchmarks
Price Chart
25
Health
Poor
Bearish
auto_awesome

Analytical Summary

RELMADA THERAPEUTICS, INC. faces fundamental challenges with weakness in Return on Common Equity (%). The fundamentals warrant careful consideration of downside risks.

Market Cap $194.6M
Dividend Yield
Revenue Growth
Op. Margin None
ROIC -54.0%
FCF / Share $-1.16
Trailing P/E
Price / Book 4.2x
FCF Yield
Debt / Equity
info Valuation on last close. End-of-day price, Aug 7, 2026.

15-Year Financial Trajectory

Annual
Metric Value Trend Year over Year Percentile
Net Income Profit after all expenses
$-57.39M
↑ +28.3%
FCF / Share Free cash flow per share
$-1.16
↑ +32.4%
trending_up

Bullish Indicators

  • No bullish signals detected.
warning

Bearish Risks

  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Returns
13
Cash Quality
54

bar_chart Data from SEC EDGAR XBRL filings

Synced 1 week ago 15 years · 58 quarters